1. Home
  2. HURA vs BKTI Comparison

HURA vs BKTI Comparison

Compare HURA & BKTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HURA
  • BKTI
  • Stock Information
  • Founded
  • HURA 2009
  • BKTI 1997
  • Country
  • HURA United States
  • BKTI United States
  • Employees
  • HURA N/A
  • BKTI N/A
  • Industry
  • HURA
  • BKTI Radio And Television Broadcasting And Communications Equipment
  • Sector
  • HURA
  • BKTI Technology
  • Exchange
  • HURA Nasdaq
  • BKTI Nasdaq
  • Market Cap
  • HURA 96.5M
  • BKTI 99.9M
  • IPO Year
  • HURA N/A
  • BKTI N/A
  • Fundamental
  • Price
  • HURA $3.48
  • BKTI $44.97
  • Analyst Decision
  • HURA Strong Buy
  • BKTI Strong Buy
  • Analyst Count
  • HURA 2
  • BKTI 1
  • Target Price
  • HURA $12.00
  • BKTI $40.00
  • AVG Volume (30 Days)
  • HURA 272.1K
  • BKTI 33.7K
  • Earning Date
  • HURA 05-15-2025
  • BKTI 03-27-2025
  • Dividend Yield
  • HURA N/A
  • BKTI N/A
  • EPS Growth
  • HURA N/A
  • BKTI N/A
  • EPS
  • HURA N/A
  • BKTI 2.25
  • Revenue
  • HURA N/A
  • BKTI $76,592,000.00
  • Revenue This Year
  • HURA N/A
  • BKTI $3.94
  • Revenue Next Year
  • HURA $221.29
  • BKTI $4.90
  • P/E Ratio
  • HURA N/A
  • BKTI $19.93
  • Revenue Growth
  • HURA N/A
  • BKTI 3.37
  • 52 Week Low
  • HURA $1.80
  • BKTI $11.67
  • 52 Week High
  • HURA $14.60
  • BKTI $44.97
  • Technical
  • Relative Strength Index (RSI)
  • HURA N/A
  • BKTI 75.56
  • Support Level
  • HURA N/A
  • BKTI $28.35
  • Resistance Level
  • HURA N/A
  • BKTI $43.34
  • Average True Range (ATR)
  • HURA 0.00
  • BKTI 2.90
  • MACD
  • HURA 0.00
  • BKTI 1.56
  • Stochastic Oscillator
  • HURA 0.00
  • BKTI 100.00

About HURA TuHURA Biosciences Inc. Common Stock

TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.

About BKTI BK Technologies Corporation

BK Technologies Corp a holding company, operates primarily through its subsidiary, BK Technologies, Inc., specializing in designing, manufacturing, and marketing wireless communications equipment. Its Radio business unit offers two-way land mobile radios (LMRs) serving government and public safety markets, as well as industrial and commercial enterprises. The SaaS business unit focuses on public safety smartphone applications, enhancing first responders' safety and efficiency. The BKRplay application, tethered to BK radios, amplifies user capabilities, expanding the reach of their radio sales. Its product portfolio consists of two-way land mobile radios, handheld radios, radios installed in vehicles.

Share on Social Networks: